BioWorld

Sep. 29, 2006

View Archived Issues

FDA Clears Amgen's Vectibix, Adds To ImClone's Troubles

Late Wednesday, the FDA approved the next in a growing line of targeted cancer therapies, Amgen Inc.'s Vectibix (panitumumab). (BioWorld Today) Read More

Athenagen Series B Garners $50M For Alzheimer's, AMD

Read More

Grant Gives Alnylam $23M For Anti-Ebola Virus Work

Read More

Startup Alvine Aims At Celiac Disease, Closes $21M Round

Read More

Other News To Note

Read More

Clinic Roundup

Read More